What Makes Allergan an Attractive Target for Actavis?

The transcript discusses Actavis's interest in acquiring Allergan for over $60 billion, surpassing a hostile bid from Valeant backed by Bill Ackman. The deal is complex, with historical context involving multiple companies. Current negotiations have Actavis and Allergan close to an agreement, with Allergan opposing Valeant due to its reputation for cutting R&D. Financial challenges exist due to high valuations. Legal issues and investor reactions are also significant, with potential legal actions against Ackman for his stock accumulation methods.

Which company is Actavis in talks to acquire?

• Omega

• Salix

• Allergan

• Valeant

Why is Allergan opposed to being acquired by Valeant?

• Valeant is known for cutting R&D

• Valeant is a new company

• Valeant's offer is too high

• Valeant has a better reputation

What is the main financial challenge Actavis faces in acquiring Allergan?

• Regulatory issues

• Lack of investor interest

• Actavis's low trading value

• Allergan's high trading value

What legal issue is Bill Ackman potentially facing regarding his Allergan shares?

• Unauthorized voting rights

• Illegal stock manipulation

• Tax evasion

• Insider trading

What did the recent court ruling allow Bill Ackman to do?

• Sell his shares

• Merge with another company

• Vote his shares in a proxy fight

• Increase his shareholding